Fig. 4

LRRK2 kinase activity controls cAMP levels through PDE4. a Quantification of cAMP levels in BV2 cells treated with GSK or DMSO as control (CTR). cAMP levels are normalized for total protein concentration in each sample. Data are representative of five independent experiments (bars represent the mean ± SEM; unpaired t test; *p < 0.05). b Expression of cAMP-specific PDEs generated from a RNA sequencing profile performed on WT primary microglia cells. Data are representative of five independent samples (bars represent the mean ± SEM; one-way ANOVA with Tukey’s post-test; *p < 0.05, *** p < 0.001). c BV2 cell lysates treated with rolipram or DMSO as control (CTR) were subjected to immunoblotting using NF-κB P-p50 and total p50 antibodies. Quantification of NF-κB P-p50 is normalized for total p50 protein. Data are representative of three independent experiments (bars represent the mean ± SEM; unpaired t test; *p < 0.05). d BV2 cell lysates treated with rolipram, rolipram and GSK, or DMSO as control (CTR) were subjected to immunoblotting using NF-κB P-p50 and total p50 antibodies. Quantification of NF-κB P-p50 is normalized for total p50 protein. Data are representative of three independent experiments (bars represent the mean ± SEM; one-way ANOVA with Tukey’s post-test; *p < 0.05)